Protective effect of <i>Clostridium tyrobutyricum</i> in acute dextran sodium sulphate-induced colitis: differential regulation of tumour necrosis factor-α and interleukin-18 in BALB/c and severe combined immunodeficiency mice

Hudcovic, Tomáš; Kolínská, J; Klepetar, J.; Štěpánková, Renata; Řezanka, Tomáš; Šrůtková, Dagmar; Schwarzer, Martin; Erban, V.; Du, Zhenggui; Wells, Jerry M.; Hrncírová, L; Tlaskalová‐Hogenová, Helena; Kozáková, Hana

doi:10.1111/j.1365-2249.2011.04498.x

Cited by 45 publications

(39 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, several recent studies focusing on the role of orally given butyrate producing bacteria like Butyricicoccus spp. or Clostridium tyrobutyricum, have revealed that the bacteria increase the butyrate levels in the colon and subsequently cure UC (Hudcovic et al, 2012;Eeckhaut et al, 2013). All these facts and our own results in this study consistently indicate that orally given butyrate could be a potential route to treat UC.…”

Section: Discussionsupporting

confidence: 74%

Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats

Malago

Sangu²

2015

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Intrarectal infusion of butyrate improves colorectal disorders including ulcerative colitis (UC). However, it is not established whether systemically administered butyrate benefits such patients. The current study aimed at exploring and comparing the potential of intraperitoneally, intrarectally, and orally administered butyrate against acetic acid (AA)-induced UC in rats. Intrarectal administration of 2 ml of 50% AA was done after or without prior treatment of rats for 7 consecutive days with 100 mg/kg sodium butyrate (SB) intraperitoneally, intrarectally, or orally. Rats were sacrificed after 48 h of AA-treatment. Subsequently, colon sections were processed routinely for histopathological examination. We clinically observed diarrhea, loose stools, and hemoccult-positive stools, and histologically, epithelial loss and ulceration, crypt damage, goblet cell depletion, hemorrhage, and mucosal infiltration of inflammatory cells. The changes were significantly reduced by intraperitoneal, intrarectal, or oral butyrate, with intraperitoneal butyrate exhibiting the highest potency. It is concluded that intraperitoneal administration of butyrate abrogates the lesions of AA-induced UC and its potency surpasses that of intrarectal or oral butyrate.

show abstract

Section: Discussionsupporting

confidence: 74%

Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats

Malago

Sangu²

2015

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…45,64 Furthermore, administration of Clostridium tyrobutyricum depressed expression of proinflammatory cytokines such as tumor necrosis factor-a and interleukin-18 in the descending colon of dextran sodium sulfate-treated mice. 59 Similar results have also been described in cytokine-mediated gastrointestinal diseases, 65 alcoholinduced inflammation, 66,67 and even chemotherapy-induced mucositis. 34 Besides, administration of probiotics (Jinshuangqi tablets) for 7 days significantly improved levels of IgA, IgG, IgM, interelukin-2, and CD4þ in the serum of colorectal cancer patients, demonstrating the capacity for probiotics to modulate adaptive immunity.…”

Section: Probiotics and Immunitysupporting

confidence: 68%

“…and Clostridium tyrobutyricum to adjust mucin secretion could therefore play a pivotal role in restoring microbiota composition and mucosal immunity in chemotherapy-treated patients. [58][59][60] Furthermore, certain probiotics have the potential to modulate cell kinetics by adjusting homeostasis between apoptosis and proliferation. For example, Lactobacillus rhamnosus regulated cellular proliferation and migration and mitogen-activated protein kinase pathways, responsible for cell proliferation, differentiation, and cytoprotection.…”

Section: Maintenance Of the Gut Barriermentioning

confidence: 99%

Newly Developed Synbiotics and the Chemotherapy-Damaged Gut

Wang

Bastian

Howarth

2013

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Mucositis is a common side-effect of cancer chemotherapy and radiotherapy. Features of mucositis include erythema, ulceration, and inflammation of the gastrointestinal tract accompanied by clinical symptoms of abdominal pain and digestive disturbances. New treatment strategies are required. Experimental evidence is accumulating showing therapeutic promise for new nutraceutical agents including probiotic bacteria, probiotic-derived factors, prebiotics, and plant extracts. However, the targeted development of new combinations of these agents (synbiotics) to combat mucositis remains largely unexplored. The current review addresses the potential for these nutraceutical agents to reduce the severity of chemotherapy-damaged mucositis by strategically aligning their underlying mechanism of action with features of mucositis pathogenesis. The potential for certain plant extracts to act as prebiotics, in combination with probiotics or their derived factors, is further investigated. These unique synbiotic formulations could form the basis of a new naturally sourced adjunctive approach to cancer chemotherapy.

show abstract

“…Hence, conventionalization with the whole gut microbiota and the introduction of a single bacterial strain in GF mice appear to have opposite consequences for small intestinal ANGPTL4 expression. Interestingly, C. tyrobutyricum was successfully used to alleviate DSS-induced colitis in mouse models (27). Butyrate-driven ANGPTL4 may therefore participate in the anti-inflammatory effects of SCFAs within the GI tract because SCFAs have been shown previously to protect mice from experimental colitis (49).…”

Section: Discussionmentioning

confidence: 99%

“…We set out to investigate the impact of a single butyrate-producing bacterial species on intestinal ANGPTL4 expression. Male C57Bl/6J GF mice were monocolonized from birth with C. tyrobutyricum (DSM 2637), Table 1 which is able to ferment a wide range of carbohydrates into butyric acid (27). ANGPTL4 expression in the ileum and in colonic epithelial cells was higher in the monoassociated mice compared with the GF mice (Fig.…”

Section: Butyrate Induces Angptl4 Expression In a Ppar-␥-independent mentioning

confidence: 99%

ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways

Korecka

Wouters

Cultrone

et al. 2013

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

-Short-chain fatty acids (SCFAs), such as butyrate and propionate, are metabolic products of carbohydrate fermentation by the microbiota and constitute the main source of energy for host colonocytes. SCFAs are also important for gastrointestinal health, immunity, and host metabolism. Intestinally produced angiopoietin-like protein 4 (ANGPTL4) is a secreted protein with metabolism-altering properties and may offer a route by which microbiota can regulate host metabolism. Peroxisome proliferator-activated receptor (PPAR)-␥ has previously been shown to be involved in microbiota-induced expression of intestinal ANGPTL4, but the role of bacterial metabolites in this process has remained elusive. Here, we show that the SCFA butyrate regulates intestinal ANGPTL4 expression in a PPAR-␥-independent manner. Although PPAR-␥ is not required for butyrate-driven intestinal ANGPTL4 expression, costimulating with PPAR-␥ ligands and SCFAs leads to additive increases in ANGPTL4 levels. We suggest that PPAR-␥ and butyrate rely on two separate regulatory sites, a PPAR-responsive element downstream the transcription start site and a butyrate-responsive element(s) within the promoter region, 0.5 kb upstream of the transcription start site. Furthermore, butyrate gavage and colonization with Clostridium tyrobutyricum, a SCFA producer, can independently induce expression of intestinal ANGPTL4 in germ-free mice. Thus, oral administration of SCFA or use of SCFA-producing bacteria may be additional routes to maintain intestinal ANGPTL4 levels for preventive nutrition or therapeutic purposes.short-chain fatty acids; peroxisome proliferator-activated receptor-␥; fasting-induced adipose factor; angiopoietin-like protein 4; Clostridium tyrobutyricum THE HUMAN GASTROINTESTINAL (GI) tract has long been perceived as an organ with purely digestive functions. This perception has radically changed over the last decades as it emerged that the function of the GI tract is not only limited to energy uptake but also affects regulatory processes with wide-ranging systemic effects. These are either directly related to its digestive functions or independent ones impacting on local and systemic inflammation (reviewed in Ref. This crosstalk contributes among other things to the physiological state of the IEC including maturation and the integrity of the overall epithelial barrier (53). The importance of a well-regulated response to the intestinal microbiota and its metabolites has repeatedly been shown to be crucial to the health of the host (reviewed in Refs. 12 and 31).Mouse studies have also linked intestinal colonization to the capacity of energy utilization and weight gain (5, 6). One mechanism implied in this process is the regulation of angiopoietin-like protein 4 (ANGPTL4) expression in the intestinal epithelium. ANGPTL4 is a secreted protein with a variety of functions ranging from regulation of lipid and glucose homeostasis to inhibition of cell migration and angiogenesis (reviewed in Ref. 21). The NH 2 -terminal domain of ANGPTL4 inhibits lipoprote...

show abstract

Protective effect of Clostridium tyrobutyricum in acute dextran sodium sulphate-induced colitis: differential regulation of tumour necrosis factor-α and interleukin-18 in BALB/c and severe combined immunodeficiency mice

Cited by 45 publications

References 52 publications

Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats

Intraperitoneal administration of butyrate prevents the severity of acetic acid colitis in rats

Newly Developed Synbiotics and the Chemotherapy-Damaged Gut

ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells utilizes independent pathways

Contact Info

Product

Resources

About